Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-08-14
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited and gene-based therapies across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, and diabetes.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved trust anchor, but breadth still decides value
The company already has what many gene-editing peers still lack: an approved product and real regulatory trust. The next valuation step depends on proving that this success can repeat across wholly owned assets with better control over economics.

Analysis

Thesis
CRISPR Therapeutics has already cleared the hardest trust gate with CASGEVY; if that launch converts into steadier economics and just one or two wholly owned programs become commercially credible, the company can rerate from cash-backed science optionality into a repeatable gene-medicine platform by 2031.
Last Economy Alignment
AI helps target design, trial learning, and process control, but value capture still sits in IP, clinical data, manufacturing, and regulatory trust. That makes CRSP a real beneficiary of cheaper cognition, though biology, reimbursement, and Vertex-mediated economics keep it below true infrastructure winners.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
The upside case does not require every program to work. A steadier CASGEVY ramp can fund time and trust, while positive human data from one or two wholly owned branches could shift investor framing from approved-asset-plus-cash to multi-franchise gene medicine. That combination supports a meaningful rerating, but the partner-controlled flagship and remaining proof gates keep the outcome in fast-growth rather than hypergrowth territory.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risk is proof conversion, not immediate funding. CRISPR must show that CASGEVY can become a steadier economic engine and that at least one wholly owned program can deliver durable, manufacturable, commercially usable human data. If not, the company can remain trapped as a partner-mediated approved asset plus a pipeline valued mostly as scientific optionality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.53
They do not sell software that AI can copy; they sell regulated therapies, manufacturing know-how, and clinical trust, which stay scarce even when design work gets cheaper. AI should make the science engine better, but biology, reimbursement, and a partner-controlled flagship still limit how fast value can compound.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case